MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $129.62 million. The enterprise value is $40.25 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 107.12 million shares outstanding. The number of shares has increased by 1.28% in one year.
| Current Share Class | 107.12M |
| Shares Outstanding | 107.12M |
| Shares Change (YoY) | +1.28% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 62.10% |
| Float | 97.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.01 |
| Forward PS | 4.00 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.04, with a Debt / Equity ratio of 0.10.
| Current Ratio | 12.04 |
| Quick Ratio | 10.88 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.30% and return on invested capital (ROIC) is -11.90%.
| Return on Equity (ROE) | -21.30% |
| Return on Assets (ROA) | -11.32% |
| Return on Invested Capital (ROIC) | -11.90% |
| Return on Capital Employed (ROCE) | -20.85% |
| Weighted Average Cost of Capital (WACC) | 11.33% |
| Revenue Per Employee | $354,802 |
| Profits Per Employee | -$429,879 |
| Employee Count | 91 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.70% in the last 52 weeks. The beta is 1.57, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -46.70% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 71.92 |
| Average Volume (20 Days) | 1,232,017 |
Short Selling Information
The latest short interest is 4.72 million, so 4.41% of the outstanding shares have been sold short.
| Short Interest | 4.72M |
| Short Previous Month | 5.24M |
| Short % of Shares Out | 4.41% |
| Short % of Float | 4.84% |
| Short Ratio (days to cover) | 5.00 |
Income Statement
In the last 12 months, MaxCyte had revenue of $32.29 million and -$39.12 million in losses. Loss per share was -$0.37.
| Revenue | 32.29M |
| Gross Profit | 25.99M |
| Operating Income | -38.42M |
| Pretax Income | -39.12M |
| Net Income | -39.12M |
| EBITDA | -34.16M |
| EBIT | -38.42M |
| Loss Per Share | -$0.37 |
Full Income StatementBalance Sheet
The company has $106.85 million in cash and $17.49 million in debt, with a net cash position of $89.37 million or $0.83 per share.
| Cash & Cash Equivalents | 106.85M |
| Total Debt | 17.49M |
| Net Cash | 89.37M |
| Net Cash Per Share | $0.83 |
| Equity (Book Value) | 167.89M |
| Book Value Per Share | 1.57 |
| Working Capital | 112.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.17 million and capital expenditures -$1.19 million, giving a free cash flow of -$29.36 million.
| Operating Cash Flow | -28.17M |
| Capital Expenditures | -1.19M |
| Depreciation & Amortization | 4.26M |
| Net Borrowing | n/a |
| Free Cash Flow | -29.36M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
Gross margin is 80.51%, with operating and profit margins of -119.01% and -121.16%.
| Gross Margin | 80.51% |
| Operating Margin | -119.01% |
| Pretax Margin | -121.16% |
| Profit Margin | -121.16% |
| EBITDA Margin | -105.80% |
| EBIT Margin | -119.01% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.28% |
| Shareholder Yield | -1.28% |
| Earnings Yield | -30.18% |
| FCF Yield | -22.65% |
Analyst Forecast
The average price target for MaxCyte is $4.11, which is 239.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.11 |
| Price Target Difference | 239.67% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 31.34% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 2.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.32 |
| Piotroski F-Score | 1 |
